Drug intelligence / Profile preview

KIND-014

Development stage: Preclinical
Lead developer: Elanco
Modality: Small Molecules

Overview

**KIND-014** is a novel therapeutic developed by KindredBio for the treatment of equine gastric ulcers in horses. In a pilot effectiveness study announced in 2018, it demonstrated positive results, indicating efficacy in managing this condition common in performance horses. Specific details on its mechanism of action, formulation, or active ingredients are not publicly detailed beyond its designation as a veterinary product.[11][13]

Beyond the preview

Go deeper on KIND-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIND-014.

Explore the full profile